{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-011211","form_type":"8-K","ticker":null,"cik":"0001267813","company_name":"MARINUS PHARMACEUTICALS, INC.","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.159477+00:00","generated_at":"2026-05-26T23:15:05.367197+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","5.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Marinus acquired by Immedica for $0.55/share; merger completed, stock to be delisted","bullets":["Tender offer closed Feb 6 with ~67.4% of shares tendered; merger effective Feb 11, 2025.","Aggregate consideration ~$32.3M; shareholders receive $0.55 cash per share.","Marinus common stock to cease trading on Nasdaq; company becomes Immedica subsidiary.","All directors and officers replaced; Anders Edvell named CEO, Simon Falk Treasurer, Nina Fleck Secretary."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-011211","json":"https://secwatch.observer/filing/0001104659-25-011211.json","markdown":"https://secwatch.observer/filing/0001104659-25-011211.md","text":"https://secwatch.observer/filing/0001104659-25-011211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/tm256024d9_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:15:05.367197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e9f9330bd","claim":"Scott Braunstein departed as Director at MARINUS PHARMACEUTICALS, INC..","evidence_excerpt":"each of Scott Braunstein, Tim Mayleben, Elan Ezickson, Seth Fischer, Marvin Johnson, and Christine Silverstein ceased to be a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"0ec83e0271","claim":"Christina Shafer departed as Chief Commercial Officer at MARINUS PHARMACEUTICALS, INC..","evidence_excerpt":"Christina Shafer (Chief Commercial Officer) ... ceased to be officers of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be an officer"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"19d4687e67","claim":"Christine Silverstein departed as Director at MARINUS PHARMACEUTICALS, INC..","evidence_excerpt":"each of Scott Braunstein, Tim Mayleben, Elan Ezickson, Seth Fischer, Marvin Johnson, and Christine Silverstein ceased to be a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5be9176a4b","claim":"Nina Fleck was appointed as Director at MARINUS PHARMACEUTICALS, INC..","evidence_excerpt":"Simon Falk and Nina Fleck became the directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"63d6804175","claim":"Scott Braunstein departed as President and Chief Executive Officer at MARINUS PHARMACEUTICALS, INC..","evidence_excerpt":"Mr. Braunstein ceased to be President and Chief Executive Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be President and Chief Executive Officer"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"85f8056d89","claim":"Anders Edvell was appointed as President and Chief Executive Officer at MARINUS PHARMACEUTICALS, INC..","evidence_excerpt":"Anders Edvell was appointed President and Chief Executive Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"9120737049","claim":"Simon Falk was appointed as Treasurer at MARINUS PHARMACEUTICALS, INC..","evidence_excerpt":"Simon Falk was appointed Treasurer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Treasurer"}],"fact_type":"executive_change"},{"claim_id":"c8c3f2259e","claim":"Simon Falk was appointed as Director at MARINUS PHARMACEUTICALS, INC..","evidence_excerpt":"Simon Falk and Nina Fleck became the directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"became director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ccfd7d77af","claim":"Nina Fleck was appointed as Secretary at MARINUS PHARMACEUTICALS, INC..","evidence_excerpt":"Nina Fleck was appointed Secretary of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Secretary"}],"fact_type":"executive_change"},{"claim_id":"da4fd87897","claim":"Marvin Johnson departed as Director at MARINUS PHARMACEUTICALS, INC..","evidence_excerpt":"each of Scott Braunstein, Tim Mayleben, Elan Ezickson, Seth Fischer, Marvin Johnson, and Christine Silverstein ceased to be a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"db1646ef73","claim":"Tim Mayleben departed as Director at MARINUS PHARMACEUTICALS, INC..","evidence_excerpt":"each of Scott Braunstein, Tim Mayleben, Elan Ezickson, Seth Fischer, Marvin Johnson, and Christine Silverstein ceased to be a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e0c4fe3a23","claim":"Elan Ezickson departed as Director at MARINUS PHARMACEUTICALS, INC..","evidence_excerpt":"each of Scott Braunstein, Tim Mayleben, Elan Ezickson, Seth Fischer, Marvin Johnson, and Christine Silverstein ceased to be a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"fe866b4f94","claim":"Seth Fischer departed as Director at MARINUS PHARMACEUTICALS, INC..","evidence_excerpt":"each of Scott Braunstein, Tim Mayleben, Elan Ezickson, Seth Fischer, Marvin Johnson, and Christine Silverstein ceased to be a director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to be a director"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"c5f4b7a6c870222de205ba645f8b0403ecea2255","claim":"MARINUS PHARMACEUTICALS, INC. underwent a change of control involving Immedica Pharma AB for $0.55 per share (closed 2025-02-11).","evidence_excerpt":"a cash tender offer to acquire all of the outstanding shares of common stock (the “ Company Common Stock ”), par value $0.001 per share, of the Company (the “ Shares ”), for $0.55 per share (such amount, as it may be adjusted in accordance with the Merger Agreement, the “ Offer Price ”), in cash, subject to any applicable withholding taxes and without","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267813/000110465925011211/0001104659-25-011211-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Immedica Pharma AB"},{"label":"Consideration","value":"$0.55 per share"},{"label":"Closing","value":"2025-02-11"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}